Top Essay Writers
Our top essay writers are handpicked for their degree qualification, talent and freelance know-how. Each one brings deep expertise in their chosen subjects and a solid track record in academic writing.
Simply fill out the order form with your paper’s instructions in a few easy steps. This quick process ensures you’ll be matched with an expert writer who
Can meet your papers' specific grading rubric needs. Find the best write my essay assistance for your assignments- Affordable, plagiarism-free, and on time!
Posted: March 18th, 2024
Table of Contents . Page .
1 Student Declaration 3
Students often ask, “Can you write my essay in APA or MLA?”—and the answer’s a big yes! Our writers are experts in every style imaginable: APA, MLA, Chicago, Harvard, you name it. Just tell us what you need, and we’ll deliver a perfectly formatted paper that matches your requirements, hassle-free.
2 Abstract 4
3 Introduction 5
4 Objectives 6
5 Methodology 6 – 10
Absolutely, it’s 100% legal! Our service provides sample essays and papers to guide your own work—think of it as a study tool. Used responsibly, it’s a legit way to improve your skills, understand tough topics, and boost your grades, all while staying within academic rules.
6 Results 7 – 21
7 Discussion 22 – 23
8 Conclusion 24
Our pricing starts at $10 per page for undergrad work, $16 for bachelor-level, and $21 for advanced stuff. Urgency and extras like top writers or plagiarism reports tweak the cost—deadlines range from 14 days to 3 hours. Order early for the best rates, and enjoy discounts on big orders: 5% off over $500, 10% over $1,000!
9 Acknowledgements 25
10 References 26 – 29
11 Appendices 30
Abstract
Yes, totally! We lock down your info with top-notch encryption—your school, friends, no one will know. Every paper’s custom-made to blend with your style, and we check it for originality, so it’s all yours, all discreet.
Introduction: Molecular targeted therapy has been gaining traction in the treatment of advanced non-small cell lung cancer (NSCLC) in place of traditional standard chemotherapy. Given the growing significance of molecular agents, it is crucial for us to have an understanding of the genetic profile of NSCLC patients and assess the efficacy of targeted agents in terms of measurable outcomes such as progression free survival (PFS), overall survival (OS), and response rate (RR). Additionally, knowledge of treatment-resistant mutations will also play a crucial role in the care of patients with advanced NSCLC.
Objectives: This review aims to analyse the current literature on (i) frequencies of genetic mutations in different populations, (ii) demographic, clinical and histological factors associated with each mutation, (iii) efficacies of the various classes of molecular agents, and (iv) establish the role of treatment-resistant mutations in NSCLC patients.
Methods: A literature search was performed on two databases, PubMed and Scopus to identify articles which addressed the research question. Inclusion and exclusion criteria were applied to the search results to select studies for the literature review. A total of 13 studies were critically appraised and summarised. The results of each study were further analysed and synthesised.
Results: 13 studies were included in the literature review. 4 studies highlighted the heterogeneity of genetic profiles across different populations with EGFR and KRAS mutations being prominent ones. 6 studies assessed the efficacy of targeted therapy. Out of these 6 studies, 3 showed that epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) and anaplastic lymphoma kinase (ALK) TKIs were superior to standard chemotherapy, 2 demonstrated clinical activity in B-raf proto-oncogene (BRAF) and human epidermal growth factor receptor 2 (HER2) mutation inhibitors but were unable to comment on whether they are superior to chemotherapy, and 1 concluded that MEK1/MEK2 inhibitors were non-superior to standard chemotherapy. Finally, 3 studies sought to identify mutations that conferred resistance to targeted therapy and they include (i) EGFR T790M, (ii) echinoderm microtubule associated protein like 4–anaplastic lymphoma kinase (EML4-ALK), and (iii) P13k/Akt/mTOR pathway mutations.
No way—our papers are 100% human-crafted. Our writers are real pros with degrees, bringing creativity and expertise AI can’t match. Every piece is original, checked for plagiarism, and tailored to your needs by a skilled human, not a machine.
Conclusions: The scene of molecular targets in advanced NSCLC is a heterogenous and evolving one. Key driver mutations in NSCLC include EGFR, ALK, and Kirsten ras oncogene (KRAS) mutations. Their frequencies vary in different patient populations. The ‘typical’ patient with mutation-associated NSCLC tend to be EGFR mutation positive, East Asian, female, light or non-smokers, with adenocarcinoma histology. EGFR TKIs and ALK TKIs are superior to standard chemotherapy in the treatment of advanced NSCLC but other classes of targeted therapy require more research to clarify their definitive role in the treatment of metastatic disease. A key treatment-resistant mutation for EGFR TKIs is the EGFR T790M mutation, which is fortunately low in frequency. More research is expected to be conducted in the area of molecular therapy and the treatment algorithm for NSCLC patients is expected to continually evolve.
Introduction
Lung cancer
According to the World Health Organisation (WHO), lung cancer is the leading cause of all cancers and the leading cause of cancer-related deaths (1), with 80-85% being non-small cell lung cancers (2, 3). Additionally, an estimated 50% of all lung cancer patients diagnosed have metastatic disease, where 5-year survival rates are as low as 4% (4, 5).
We’re the best because our writers are degree-holding experts—Bachelor’s to Ph.D.—who nail any topic. We obsess over quality, using tools to ensure perfection, and offer free revisions to guarantee you’re thrilled with the result, even on tight deadlines.
Genetic Profile of Non-Small Cell Lung Cancer (NSCLC) patients
Given that NSCLC forms the majority of lung cancers and is associated with key driver mutations crucial to the treatment of metastatic disease (6), it is vital for us to have an understanding of the genetic profile of this population. Examples of key mutations include epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS1, Kirsten ras oncogene (KRAS), and B-raf proto-oncogene (BRAF) mutations (7, 8).
Targeted Therapy
Over the past two decades, the management of NSCLC has become increasingly targeted. Today, treatment for metastatic NSCLC is driven by molecular agents specific to a patient’s mutational status (9). The use of EGFR tyrosine kinase inhibitors (TKIs) in patients with sensitising mutations have been supported by multiple landmark trials on the basis of greater response rates (RR) and progression free survival (PFS) than chemotherapy (10-15). This has been supported by two Cochrane reviews published in 2016 (16) and 2018 (17). The use of Crizotinib for ALK- and ROS1-mutant lung cancers has also been gaining ground (18, 19). It is expected that the treatment algorithm for NSCLC patients with driver mutations will continue to evolve as more studies continue to investigate the efficacy of new and existing molecular agents.
Our writers are top-tier—university grads, many with Master’s degrees, who’ve passed tough tests to join us. They’re ready for any essay, working with you to hit your deadlines and grading standards with ease and professionalism.
Resistance to Treatment
The use of mutational status can also be used as a predictive factor on whether a patient will be resistant to treatment (20). This allows physicians to spare patients from adverse effects of targeted therapy should benefits of response be minimal in comparison to risk of toxicity.
Objectives
This review aims to analyse the current literature on the use of molecular targets in NSCLC through the following objectives:
Always! We start from scratch—no copying, no AI—just pure, human-written work with solid research and citations. You can even get a plagiarism report to confirm it’s 95%+ unique, ready for worry-free submission.
Methods
Search Strategy
An electronic search was carried out on PubMed and Scopus to identify studies which would elucidate the research topic and achieve the objectives of this literature review.
You bet! From APA to IEEE, our writers nail every style with precision. Give us your guidelines, and we’ll craft a paper that fits your academic standards perfectly, no sweat.
The following search strategy was used for both databases:
AND
AND
Filters Activated
Yep! Use our chat feature to tweak instructions or add details anytime—even after your writer’s started. They’ll adjust on the fly to keep your essay on point.
Filters activated for the search strategy included:
No. | Filter | Specifications | Comments |
1 | Text availability | Full text | |
2 | Publication dates | Within the past 10 years | Landmark trials relevant to the topic date back as early as 10 years ago |
3 | Species | Humans | |
4 | Language | English | |
5 | Age | Adults; >19 years old | To exclude paediatric populations |
Inclusion Criteria
Exclusion Criteria
Easy—place your order online, and your writer dives in. Check drafts or updates as you go, then download the final paper from your account. Pay only when you’re happy—simple and affordable!
Study Selection Process
The search results elicited from PubMed and Scopus were combined and subsequently screened for the removal of duplicates. After which, titles and abstracts of the remaining articles were carefully assessed, with application of the inclusion and exclusion criteria.
Of the 22 abstracts deemed suitable for the literature review, those with full text articles which were not accessible either as free full text, or via the University College Cork (UCC) library portal were further excluded. The remaining 17 papers with full text were carefully read through to select 10 studies which best satisfied the inclusion and exclusion criteria. Lastly, the references of all 10 selected studies were carefully reviewed and another 3 highly relevant landmark trials were suggested for inclusion by the project supervisor, an expert in the field of medical oncology. These 3 studies satisfied the inclusion and exclusion criteria, and were thus included. The selection process is summarised in Figure 1 below and reasons for exclusion are found in Table 1.
Super fast! Our writers can deliver a quality essay in 24 hours if you’re in a pinch. Pick your deadline—standard is 10 days, but we’ll hustle for rush jobs without skimping.
Definitely! From astrophysics to literary theory, our advanced-degree writers thrive on tough topics. They’ll research deeply and deliver a clear, sharp paper that meets your level—high school to Ph.D.
We tailor your paper to your rubric—structure, tone, everything. Our writers decode academic expectations, and editors polish it to perfection, ensuring it’s grade-ready.
Figure 1. Outline of Study Selection Process
Upload your draft, tell us your goals, and our editors will refine it—boosting arguments, fixing errors, and keeping your voice. You’ll get a polished paper that’s ready to shine.
Sure! Need ideas? We’ll pitch topics based on your subject and interests—catchy and doable. Pick one, and we’ll run with it, or tweak it together.
Table 1. Overview of studies excluded
Reason for exclusion | Number | |
Abstracts | Review articles | 56 |
Case report and case series | 107 | |
Studies on clinical presentation of lung cancer | 6 | |
Studies evaluating economic, administrative, or operational aspects of the topic | 14 | |
Studies evaluating lung cancer in relation to topics apart from molecular targets | 13 | |
Studies on small cell lung cancer | 10 | |
Studies on other cancers with molecular targets | 120 | |
Studies on techniques of obtaining tissue samples or on techniques of testing for mutations | 43 | |
Studies on other lung diseases with molecular targets | 4 | |
Laboratory-based, ex-vivo studies on human tissues | 13 | |
Total | 386 | |
Full Text Articles | Not free full text, unable to access via UCC library portal, permission to access not granted | 5 |
Studies on treatment that do not have a treatment arm for molecular targeted therapy | 3 | |
Studies focused on treatment of sites of metastases | 4 | |
Total | 12 |
Results
A summary of the thirteen studies selected for this review can be found in Tables 2-4. Abbreviations used in the tables are listed in Box 1.
Box 1. Abbreviations used in the results tables
OS – overall survival |
You Want The Best Grades and That’s What We Deliver
Our top essay writers are handpicked for their degree qualification, talent and freelance know-how. Each one brings deep expertise in their chosen subjects and a solid track record in academic writing.
We offer the lowest possible pricing for each research paper while still providing the best writers;no compromise on quality. Our costs are fair and reasonable to college students compared to other custom writing services.
You’ll never get a paper from us with plagiarism or that robotic AI feel. We carefully research, write, cite and check every final draft before sending it your way.